Omitted Doxorubicin

Phase 3Small molecule

Omitted Doxorubicin is one of 3 small molecule programs targeting Leukemia, Acute Lymphoblastic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Acute LymphoblasticRecruiting

Leukemia, Acute LymphoblasticPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Leukemia, Acute Lymphoblastic

#DrugCompanyPhaseTrials

Blincyto

Amgen

Phase 3

2 2

Gleevec

Novartis

Phase 3

1 3

Omitted Doxorubicin

MMats Heyman

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2033

Phase 3Recruiting

Leukemia, Acute Lymphoblastic

NCT04307576

Clinical

Trials by Indication[1]

Leukemia, Acute Lymphoblastic1 trial

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

Recruiting·MMats Heyman·Phase 3·NCT04307576·6,430 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omitted Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omitted Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omitted Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mats Heyman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMats Heyman

Omitted Doxorubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2033

Trials by Indication[1]

Leukemia, Acute Lymphoblastic1 trial

References

Drug Info

Quick Facts

Related News